A selective Akt inhibitor produces hypotension and bradycardia in conscious rats due to inhibition of the autonomic nervous system

Toxicological Sciences

Volumn 125, Issue 2, 2012, Pages 578-585

  Renninger, Jonathan P ^a,b   Murphy, Dennis J ^b   Morel, Diane W ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Akt; Autonomic nervous system; Bradycardia; Conscious; Hypotension; Nicotinic acetylcholine receptor; Rat

Indexed keywords

1,1 DIMETHYL 4 PHENYLPIPERAZINIUM; HEXAMETHONIUM; NICOTINIC RECEPTOR; PROTEIN KINASE B INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE MONITORING; BRADYCARDIA; CARDIOVASCULAR EFFECT; DRUG MECHANISM; HEART ATRIUM; HEART RATE; HYPOTENSION; IN VIVO STUDY; ISOLATED HEART; MALE; NONHUMAN; RAT; TELEMETRY; THORACIC AORTA; VASCULAR RING; VASODILATATION;

RATTUS;

EID: 84856086637     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr316     Document Type: Article

References (27)

1. BoSmith, R. E., Briggs, I., and Sturgess, N. C. (1993). Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells. Br. J. Pharmacol. 110, 343-349.
2. Chin, Y. R., and Toker, A. (2009). Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell. Signal. 21, 470-476.
3. Condorelli, G., Drusco, A., Stassi, G., Bellacosa, A., Roncarati, R., Iaccarino, G., Russo, M. A., Gu, Y., Dalton, N., Chung, C., et al. (2002). Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99, 12333-12338.
4. Ferro, A., Coash, M., Yamamoto, T., Rob, J., Ji, Y., and Queen, L. (2004). Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. Br. J. Pharmacol. 143, 397-403.
5. Hanton, G. (2007). Preclinical cardiac safety assessment of drugs. Drugs R. D. 8, 213-228.
6. Harvey, R. D., and Lonial, S. (2007). PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol. 3, 639-647.
7. Kim, Y. K., Kim, S. J., Yatani, A., Huang, Y., Castelli, G., Vatner, D. E., Liu, J., Zhang, Q., Diaz, G., Zieba, R., et al. (2003). Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J. Biol. Chem. 278, 47622-47628.
8. Li, Q. (2007). Recent progress in the discovery of Akt inhibitors as anticancer agents. Expert Opin. Ther. Patents 17, 1077-1130.
9. Li, Y. F., LaCroix, C., and Freeling, J. (2009). Specific subtypes of nicotinic cholinergic receptors involved in sympathetic and parasympathetic cardiovascular responses. Neurosci. Lett. 462, 20-23.
10. Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, and Duggan, M. E. (2005). Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761-764.
11. LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., and Dennis, P. A. (2008). Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist. Updat. 11, 32-50.
12. Mao, K., Kobayashi, S., Jaffer, Z. M., Huang, Y., Volden, P., Chernoff, J., and Liang, Q. (2008). Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J. Mol. Cell. Cardiol. 44, 429-434.
13. National Research Council. (2011). Guide for the Care and Use of Laboratory Animals, 8th ed. The National Research Council Press, Washington, DC.
14. Nikmaram, M. R., Boyett, M. R., Kodama, I., Suzuki, R., and Honjo, H. (1997). Variation in effects of Cs+, UL-FS-49, and ZD7288 within sinoatrial node. Am. J. Physiol. 272, H2782-H2792.
15. Oudit, G. Y., Sun, H., Kerfant, B. G., Crackower, M. A., Penninger, J. M., and Backx, P. H. (2004). The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449-471.
16. Parker, M. J., Beck, A., and Luetje, C. W. (1998). Neuronal nicotinic receptor beta2 and beta4 subunits confer large differences in agonist binding affinity. Mol. Pharmacol. 54, 1132-1139.
17. Raschi, E., Vasina, V., Ursino, M. G., Boriani, G., Martoni, A., and De Ponti, F. (2010). Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol. Ther. 125, 196-218.
18. Santajuliana, D., Hornfeldt, B. J., and Osborn, J. W. (1996). Use of ganglionic blockers to assess neurogenic pressor activity in conscious rats. J. Pharmacol. Toxicol. Methods 35, 45-54.
19. Skok, V. I. (2002). Nicotinic acetylcholine receptors in autonomic ganglia. Auton. Neurosci. 97, 1-11.
20. Staal, S. P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 84, 5034-5037.
21. Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z. Q., Ma, X. L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001). AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159, 431-437.
22. Wang, N., Orr-Urtreger, A., and Korczyn, A. D. (2002). The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: Lessons from knockout mice. Prog. Neurobiol. 68, 341-360.
23. Whiteman, E. L., Cho, H., and Birnbaum, M. J. (2002). Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13, 444-451.
24. Yang, Z. Z., Tschopp, O., Baudry, A., Dummler, B., Hynx, D., and Hemmings, B. A. (2004). Physiological functions of protein kinase B/Akt. Biochem. Soc. Trans. 32, 350-354.
25. Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., and Workman, P. (2008). Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412.
26. Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., Duggan, M. E., et al. (2005). Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg. Med. Chem. Lett. 15, 905-909.
27. Zhu, G. D., Gandhi, V. B., Gong, J., Thomas, S., Woods, K. W., Song, X., Li, T., Diebold, R. B., Luo, Y., Liu, X., et al. (2007). Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J. Med. Chem. 50, 2990-3003.